Ranibizumab + Verteporfin PDT + Sham Ranibizumab + Sham verteporfin PDT
Phase 3Completed 0 views this week 0 watching⚡ Active
Interest: 40/100
40
Development Stage
✓
Pre-clinical✓
Phase 1✓
Phase 24
Phase 35
ApprovedIndication / Disease
Pathological Myopia
Conditions
Pathological Myopia
Trial Timeline
Oct 1, 2010 → Aug 1, 2012
NCT ID
NCT01217944About Ranibizumab + Verteporfin PDT + Sham Ranibizumab + Sham verteporfin PDT
Ranibizumab + Verteporfin PDT + Sham Ranibizumab + Sham verteporfin PDT is a phase 3 stage product being developed by Novartis for Pathological Myopia. The current trial status is completed. This product is registered under clinical trial identifier NCT01217944. Target conditions include Pathological Myopia.
What happened to similar drugs?
1 of 3 similar drugs in Pathological Myopia were approved
Approved (1) Terminated (0) Active (2)
Hype Score Breakdown
Clinical
17
Activity
8
Company
15
Novelty
0
Community
0
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT01217944 | Phase 3 | Completed |
Competing Products
4 competing products in Pathological Myopia
| Product | Company | Stage | Hype Score |
|---|---|---|---|
| olanzapine + sugar pill | Eli Lilly | Phase 3 | 40 |
| VEGF Trap-Eye (BAY86-5321) | Regeneron Pharmaceuticals | Phase 3 | 40 |
| Fibrin Sealant, Vapor Heated, Solvent/Detergent-treated with 500 IU/mL thrombin and synthetic aprotinin (FS VH S/D 500 s-apr) | Baxter | Phase 2 | 32 |
| Gadoversetamide | Guerbet | Approved | 33 |